On Body Delivery Systems Patents: Who Leads, Where Gaps Are 2026
On Body Delivery Systems Patents: Filing Trends and Ownership
66.4% concentration. The top 5 of 38 ranked assignees hold 71 of the 107 records in scope — 66.4% of the field sits with a small group. Volume rose from 2 records in 2017 to a peak of 26 in 2018, then settled into a steadier band; 2021 to 2024 shows a confirmed +12% rise (17 to 19 records), with 2025 and 2026 still filling in as publications catch up to filing dates.
- 1BECTON DICKINSON & CO21
- 2AMGEN INC18
- 3SANOFI AVENTIS DEUT GMBH15
- 4SHL MEDICAL AG10
- 5BAYER HEALTHCARE LLC7
See the full on body delivery systems analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on on-body delivery patents
Who holds the most patents in on-body drug delivery systems?
Ownership in this dataset is concentrated: the leading assignee holds 21 of the 107 records in scope, and the top 5 of 38 ranked assignees together hold 71 records, or 66.4% of the field. The gap to fifth place, which holds 7 records, is large, indicating one company has built a substantially deeper estate than its nearest competitors. Beyond the top ten, which together hold 89.7% of records, filing counts drop to single digits and then to one or two filings per company across the remaining ranked assignees.
What technology areas dominate on-body injector patent claims?
The A61M subclass, covering devices for administering media to the body, appears on 90.7% of the 107 records in scope, making it by far the dominant classification. A61B (diagnosis and surgery) is a distant second at 10.3%, with smaller specialist classes such as G21G, A61J, F04B, G21F, F04D and G06F each covering single-digit shares tied to radiopharmaceutical handling, containers, pumps and software elements. Because a single record can carry several IPC classes, these figures overlap rather than sum to 100%.
Is filing activity in on-body drug delivery still growing?
Filing peaked in 2018 at 26 records and has not returned to that level since, but the most recent complete span shows real growth: 17 records in 2021 rising to 19 in 2024, a 12% increase. Data from 2025 and 2026 is still incomplete because publication typically lags filing by around 18 months, so those years should not be read as a slowdown. The honest read is steady, moderate growth through the last fully reported year rather than either a boom or a decline.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on On Body Delivery Systems covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.